Well, I disagree. The tutes know full well that the stock is worth many times the current share price. They have actual analysts who figure that out, as opposed to retail thinking "oh no, the stock is down, how can I get out of this regardless of price?" Any tute with a clue who invests in clinical biotech understands the manipulation game and the timelines. They also know that management may have made mistakes but nothing that justifies this share price, or even $15.
News 
Market Data 
Discover 
